Overview Study of INBRX-109 in Conventional Chondrosarcoma Status: Recruiting Trial end date: 2024-06-01 Target enrollment: Participant gender: Summary Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. Phase: Phase 2 Details Lead Sponsor: Inhibrx, Inc.